

COVID-19 Module Long Term Care Facility: Resident Impact and Facility Capacity Pathway

Page 1 of 3		*Required to save;**Conditional				
	Facility ID:		ication Number (CCN):		
Facilit	Facility Name: Facility Type:					
*Date	for which counts/responses are reported:	/ /	*Date	Created: /	/	
Facilit	ty Capacity					
	ALL BEDS					
	*CURRENT CENSUS: Total number of be	ds that are occupie	d on the reporting	calendar day		
	•	•		•		
Reside	ent Impact for COVID-19 (SARS-CoV-2)					
	*ADMISSIONS: Number of residents admi	tted or readmitted f	rom another facil	ity who were previ	ously diagnosed	
	with COVID-19 and continue to require tran	smission-based pre	cautions. <i>Exclude</i>	<u>s</u> recovered resider	nts.	
	*POSITIVE TESTS: Enter the number of r	esidents with a <u>new</u>	<u>vly</u> positive SARS	S-CoV-2 viral test r	esult.	
	Include only residents newly positive since the	ne most recent date	data were collect	ed for NHSN repor	ting.	
Vacci	nation Status of Residents with a Newly Confi	rmed SARS-CoV-	2 Viral Test Res	ult		
			TEST TYP	E CATEGORIE	S	
		[±] Only include i	f additional tests	were performed wi	thin 2 calendar days	
		fro	m initial test. Oth	erwise, count first	test only.	
		Positive SARS- CoV-2 antigen test only [no other through the content of the con	[no other testing	**Positive SARS-CoV-2 antigen test and negative	**** Any other combination of SARS-CoV-2 NAAT (PCR) and/or antigen	
		performed]	performed]	SARS-CoV-2 NAAT (PCR).	test(s) with at least one positive test.	
**TEST TYPE: Based on the number reported for <i>Positive Tests</i> , enter the number of residents tested in each test type category. <i>The total of counts reported in each category must be equal to the count(s) reported for "Positive Tests"</i> .						
**VACCINATION STATUS (FOR CALCULATED TOTAL CONFIRMED): For positives in each test type category, indicate how many residents received COVID-19 vaccination 14 days or more before the specimen collection date.						
	NOVACC – Not vaccinated with COVID- 19 vaccine or first dose administered 13 days or less before the specimen collection date.					
	MODERNA1 - Only dose 1 of Moderna COVID-19 vaccine.					
	MODERNA - Dose 1 and ^v 2 of Moderna COVID-19 vaccine.					
ries	PFIZBION1 - Only dose 1 of Pfizer-BioNTech COVID-19 vaccine.					
al Series	PFIZBION - Dose 1 and ^v 2 of Pfizer- BioNTech COVID-19 vaccine.					

JANSSEN – Dose of Janssen COVID-19

vaccine.



	UNSPECPARTIAL1 – *One dose of COVID-19 vaccine with an unspecified manufacturer.		
	UNSPECCOMPLETE – Dose 1 and ^v 2 of COVID-19 vaccination series with unspecified manufacturer or more than 1 manufacturer.		
**Additional or Booster doses	ADDORBOOST3 – ▲ Additional dose or booster dose of COVID-19 vaccine (any manufacturer) received 14 days or more before the specimen collection date.		

CALCULATED TOTAL CONFIRMED (not editable by use	er):
Page 2 of 3	*Required to save; **Conditional
Re-Infections with SARS-CoV-2	
**RE-INFECTIONS: Based on the number reported for Positi	ive Tests, indicate how many met NHSN definition for re-infection:
SYMPTOMATIC: Based on the number reported for <i>Re</i> -symptoms consistent with COVID-19:	Infections, indicatehow many of the residents had signs and/or
ASYMPTOMATIC: Based on the number reported for <i>R</i> and/or symptoms consistent with COVID-19:	e-Infections, indicate how many of the residents did not have signs
*TOTAL DEATHS: Number of residents who have died for a Include only the number of new deaths since to	ny reason in the facility or another location: the most recent date data were reported to NHSN
**COVID-19 DEATHS: Based on the number reported for	or Total Deaths, indicate the number of residents who died from
COVID-19 or related complications, either in the facility of	or another location:
Decident Impact for Non-COVID-10 (CARC CaV 2) Decrino	tow Illnog
Resident Impact for Non-COVID-19 (SARS-CoV-2) Respira	
INFLUENZA: Number of Residents with new influenz	
RESPIRATORY ILLNESS: Number of Residents with and/or influenza (flu).	h acute respiratory illness symptoms, excluding COVID-19
Resident Impact for Co-Infections	
INFLUENZA and COVID-19: Number of residents with CoV-2 (COVID-19).	ith a confirmed co-infection with influenza (flu) and SARS-

^vSecond dose received 14 days or more before the specimen collection date; otherwise, count as only dose 1.

^{*} One dose received 14 days or more before the specimen collection date, or dose 1 and 2 received in which dose 2 was received 13 days or less before specimen collection date.

Additional dose or booster dose received 14 days or more before the specimen collection date.



CA	DC	Cal	7 7	TEC	TING

Shirts-cov-2 legilito
Since the last date of data entry in the Module, has your LTCF performed SARS-CoV-2 (COVID-19) viral testing on residents and/or staff? □ YES □ NO
** If, YES, enter the number of SARS-CoV-2 (COVID-19) viral test(s) that were performed using the following categories:
**POCRESIDENT: Since the last date of data entry in the Module, how many COVID-19 point- of-care tests has the LTCF performed on residents?
**POCSTAFF: Since the last date of data entry in the Module, how many COVID-19 point- of- care tests has the LTCF performed on staff and/or facility personnel?
**NONPOCRESIDENT: Since the last date of data entry in the Module, how many COVID-19 NON point-of-care tests has the LTCF performed on residents?
**NONPOCSTAFF: Since the last date of data entry in the Module, how many COVID-19 NON point-of-care tests has the LTCF performed on staff and/or facility personnel?
During the past two weeks, on average, how long did it take your LTCF to receive SARS-CoV-2 viral test results from NON-point-of-care tests? (<i>Select ONE</i>)
☐ Less than one day ☐ 1-2 days
\Box 3-7 days
☐ More than 7 days
□ No testing was performed in the past two weeks on residents or staff/facility personnel.
TESTINGSTAFF: Does the LTCF have the ability to perform or to obtain resources for performing SARS-CoV-2 viral testing (NAAT [PCR] or antigen) on all staff and facility personnel within the next 7 days, if needed? □ YES □ NO
TESTINGRESIDENT: Does the LTCF have the ability to perform or to obtain resources for performing SARS-CoV-2 viral testing (NAAT [PCR] or antigen) on all current residents within the next 7 days, if needed? □ YES □ NO
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).
CDC estimates the average public reporting burden for this collection of information as 60 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering, and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-1317). CDC 57.144 (Front) v.10 (07-2021).